Document Detail


Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after intravenous tissue-type plasminogen activator therapy.
MedLine Citation:
PMID:  22811464     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND PURPOSE: The malignant profile has been associated with poor outcomes after reperfusion in the 3- to 6-hour time window. The aim of this study was to estimate the incidence and prognostic implications of the malignant profile, as identified by CT perfusion, in intravenous tissue-type plasminogen activator-treated patients who were imaged <3 hours from stroke onset.
METHODS: The incidence of the malignant profile, based on the previously published optimal perfusion-weighted imaging definition, was assessed in consecutive patients using a fully automated software program (RApid processing of Perfusion and Diffusion [RAPID]). A receiver operating characteristic curve analysis was done to identify time to maximum and core volume thresholds that optimally identify patients with poor outcome (modified Rankin Scale 5-6).
RESULTS: Forty-two patients had an interpretable CT perfusion performed within 3 hours of symptom onset. Mean age was 74±14 years and median (interquartile range) National Institutes of Stroke Scale score was 13 (6-19). Four patients (9.5%) met the prespecified criteria for the malignant profile and all 4 had poor outcome. Receiver operating characteristic analysis determined that the best CT perfusion measure to identify patients with poor outcome was a cerebral blood flow based infarct core >53 mL (100% specificity and 67% sensitivity). This criterion identified 5 patients as malignant (12%). The poor outcome rate in these patients was 100% versus 7.1% in the 37 nonmalignant patients (P<0.001).
CONCLUSIONS: The incidence of the malignant profile on CT perfusion is approximately 10% in tissue-type plasminogen activator-eligible patients imaged within 3 hours of symptom onset. The clinical outcome of these patients is very poor despite intravenous tissue-type plasminogen activator therapy.
Authors:
Manabu Inoue; Michael Mlynash; Matus Straka; Maarten G Lansberg; Greg Zaharchuk; Roland Bammer; Gregory W Albers
Related Documents :
3877174 - Increased susceptibility of patients with cervical cord lesions to peptic gastrointesti...
11201644 - Minor head injuries: one year experience according to the new italian guideline.
12351974 - Jewelry-induced diseases of the head and neck.
1929824 - Is early prediction of outcome in severe head injury possible?
23683874 - Blinded by the uv light: how the focus on transcription-coupled ner has distracted from...
24997584 - Serum adenosine deaminase activity in cutaneous anthrax.
Publication Detail:
Type:  Journal Article     Date:  2012-07-17
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  43     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-28     Completed Date:  2012-11-05     Revised Date:  2014-06-17    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2494-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cerebral Infarction / drug therapy,  pathology
Female
Fibrinolytic Agents / administration & dosage,  therapeutic use*
Humans
Image Processing, Computer-Assisted
Magnetic Resonance Imaging
Male
Middle Aged
Prognosis
ROC Curve
Stroke / drug therapy*,  physiopathology*
Tissue Plasminogen Activator / administration & dosage,  therapeutic use*
Tomography, X-Ray Computed
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01 NS066506/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of ...
Next Document:  Racial-Ethnic Biases, Time Pressure, and Medical Decisions.